|
US3655679A
(en)
|
1969-06-25 |
1972-04-11 |
Merck & Co Inc |
Certain aryl pyridine carboxylic acid derivatives
|
|
US3703582A
(en)
|
1970-04-20 |
1972-11-21 |
Merck & Co Inc |
Aryl pyridine carboxylic acids in the treatment of inflammation
|
|
US3894920A
(en)
|
1971-12-21 |
1975-07-15 |
Sagami Chem Res |
Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
|
|
US4016287A
(en)
|
1972-07-17 |
1977-04-05 |
Boehringer Ingelheim Gmbh |
Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
|
|
CA1261335A
(en)
|
1984-08-29 |
1989-09-26 |
Hoffmann-La Roche Limited/Hoffmann-La Roche Limitee |
Ethylenediamine monoamide derivatives
|
|
CN1023479C
(zh)
|
1985-09-27 |
1994-01-12 |
弗·哈夫曼-拉罗切有限公司 |
乙二胺的单酰胺衍生物的制备方法
|
|
TW219933B
(https=)
|
1990-02-26 |
1994-02-01 |
Lilly Co Eli |
|
|
US5405613A
(en)
|
1991-12-11 |
1995-04-11 |
Creative Nutrition Canada Corp. |
Vitamin/mineral composition
|
|
TW352384B
(en)
|
1992-03-24 |
1999-02-11 |
Hoechst Ag |
Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
|
|
DE4219158A1
(de)
|
1992-06-11 |
1993-12-16 |
Thomae Gmbh Dr K |
Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
|
|
EP0650961B1
(de)
|
1993-11-02 |
1997-03-05 |
Hoechst Aktiengesellschaft |
Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
|
|
ES2101420T3
(es)
|
1993-11-02 |
1997-07-01 |
Hoechst Ag |
Esteres-amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
|
|
NZ270267A
(en)
|
1993-12-30 |
1997-03-24 |
Hoechst Ag |
3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
|
|
DE4410423A1
(de)
|
1994-03-25 |
1995-09-28 |
Hoechst Ag |
Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
DE4410480A1
(de)
|
1994-03-25 |
1995-09-28 |
Hoechst Ag |
Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
US5789426A
(en)
|
1995-01-20 |
1998-08-04 |
Cornell Research Foundation, Inc. |
Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
|
|
IL135495A
(en)
|
1995-09-28 |
2002-12-01 |
Hoechst Ag |
Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
|
|
JPH09221476A
(ja)
|
1995-12-15 |
1997-08-26 |
Otsuka Pharmaceut Co Ltd |
医薬組成物
|
|
WO1997041103A1
(de)
|
1996-04-30 |
1997-11-06 |
Hoechst Aktiengesellschaft |
3-alkoxypyridin-2-carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel
|
|
DE19620041A1
(de)
|
1996-05-17 |
1998-01-29 |
Merck Patent Gmbh |
Adhäsionsrezeptor-Antagonisten
|
|
DE19650215A1
(de)
|
1996-12-04 |
1998-06-10 |
Hoechst Ag |
3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
|
|
EP1024134A4
(en)
|
1997-10-09 |
2003-05-14 |
Ono Pharmaceutical Co |
DERIVATIVES OF AMINOBUTANIC ACID
|
|
DE19746287A1
(de)
|
1997-10-20 |
1999-04-22 |
Hoechst Marion Roussel De Gmbh |
Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
|
|
ATE273277T1
(de)
|
1998-03-23 |
2004-08-15 |
Aventis Pharma Inc |
Piperidinyl- und n-amidinopiperidinyl-derivate
|
|
US6159379A
(en)
|
1999-05-04 |
2000-12-12 |
Baker Hughes Incorporated |
Organic ammonium salts for the removal of water soluble organics in produced water
|
|
JP2001048786A
(ja)
|
1999-08-05 |
2001-02-20 |
Yamanouchi Pharmaceut Co Ltd |
三環式ヘテロアリール誘導体
|
|
ES2312422T3
(es)
|
2000-03-22 |
2009-03-01 |
PHARMACIA & UPJOHN COMPANY LLC |
Formulacion de comprimido de oxazolidinona.
|
|
US6589758B1
(en)
|
2000-05-19 |
2003-07-08 |
Amgen Inc. |
Crystal of a kinase-ligand complex and methods of use
|
|
US6849718B2
(en)
|
2001-03-20 |
2005-02-01 |
Dana Farber Cancer Institute, Inc. |
Muteins of hypoxia inducible factor alpha and methods of use thereof
|
|
US6855510B2
(en)
|
2001-03-20 |
2005-02-15 |
Dana Farber Cancer Institute, Inc. |
Pharmaceuticals and methods for treating hypoxia and screening methods therefor
|
|
JP4590157B2
(ja)
|
2001-03-21 |
2010-12-01 |
アイシス イノヴェイション リミテッド |
アッセイ、方法および手段
|
|
SE0101327D0
(sv)
|
2001-04-12 |
2001-04-12 |
Astrazeneca Ab |
New crystalline forms
|
|
US6566088B1
(en)
|
2001-10-04 |
2003-05-20 |
Board Of Regents, The University Of Texas System |
Prolyl-4-hydroxylases
|
|
GB0124941D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
CN102552263A
(zh)
|
2001-12-06 |
2012-07-11 |
法布罗根股份有限公司 |
提高内源性红细胞生成素(epo)的方法
|
|
EP1556033A4
(en)
|
2002-05-17 |
2006-05-31 |
Celgene Corp |
METHODS AND COMPOSITIONS USING CYTOKINE INHIBITOR SELECTIVE MEDICAMENTS FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES
|
|
WO2004019868A2
(en)
|
2002-08-29 |
2004-03-11 |
Merck & Co., Inc. |
N-biarylmethyl aminocycloalkanecarboxamide derivatives
|
|
WO2004035812A2
(en)
|
2002-10-16 |
2004-04-29 |
Isis Innovation Limited |
Asparaginyl hydroxylases and modulators thereof
|
|
CA2506799A1
(en)
|
2002-11-21 |
2004-06-10 |
Eli Lilly And Company |
Mixed lineage kinase modulators
|
|
US8124582B2
(en)
|
2002-12-06 |
2012-02-28 |
Fibrogen, Inc. |
Treatment of diabetes
|
|
US7618940B2
(en)
|
2002-12-06 |
2009-11-17 |
Fibrogen, Inc. |
Fat regulation
|
|
US7183287B2
(en)
|
2003-04-03 |
2007-02-27 |
Pharmacia Corporation |
Substituted pyrimidinones
|
|
WO2005007192A2
(en)
|
2003-06-06 |
2005-01-27 |
Fibrogen, Inc. |
Cytoprotection through the use of hif hydroxylase inhibitors
|
|
US8614204B2
(en)
|
2003-06-06 |
2013-12-24 |
Fibrogen, Inc. |
Enhanced erythropoiesis and iron metabolism
|
|
CA2528232C
(en)
|
2003-06-06 |
2010-05-25 |
Fibrogen, Inc. |
Novel nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
|
|
GB0314129D0
(en)
|
2003-06-18 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
|
JPWO2005108370A1
(ja)
|
2004-04-16 |
2008-03-21 |
味の素株式会社 |
ベンゼン化合物
|
|
DE602005016800D1
(de)
|
2004-05-28 |
2009-11-05 |
Fibrogen Inc |
Hif-prolylhydroxylase-aktivitätstest
|
|
JP2008500951A
(ja)
|
2004-05-31 |
2008-01-17 |
田辺三菱製薬株式会社 |
二環化合物
|
|
EP1771169A1
(en)
|
2004-07-14 |
2007-04-11 |
PTC Therapeutics, Inc. |
Methods for treating hepatitis c
|
|
TW200616969A
(en)
|
2004-09-17 |
2006-06-01 |
Tanabe Seiyaku Co |
Imidazole compound
|
|
EA014249B1
(ru)
*
|
2005-01-27 |
2010-10-29 |
Алембик Лимитед |
Формуляция леветирацетама длительного высвобождения
|
|
WO2006084210A2
(en)
|
2005-02-04 |
2006-08-10 |
Regents Of The University Of California, San Diego |
Hif modulating compounds and methods of use thereof
|
|
DE102005019712A1
(de)
|
2005-04-28 |
2006-11-09 |
Bayer Healthcare Ag |
Dipyridyl-dihydropyrazolone und ihre Verwendung
|
|
US20060276477A1
(en)
|
2005-06-06 |
2006-12-07 |
Fibrogen, Inc. |
Treatment method for anemia
|
|
AU2006259352A1
(en)
|
2005-06-15 |
2006-12-28 |
Fibrogen, Inc. |
Use of HIF 1alfa modulators for treatment of cancer
|
|
WO2007033216A2
(en)
|
2005-09-12 |
2007-03-22 |
Beth Israel Deaconess Medical Center |
Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
|
|
WO2007038571A2
(en)
|
2005-09-26 |
2007-04-05 |
Smithkline Beecham Corporation |
Prolyl hydroxylase antagonists
|
|
US20090176726A1
(en)
|
2005-10-11 |
2009-07-09 |
Fisher David E |
Methods for treating mitf-related disorders
|
|
JP5202327B2
(ja)
|
2005-12-09 |
2013-06-05 |
アムジエン・インコーポレーテツド |
プロリルヒドロキシラーゼ阻害活性を示すキノロンベースの化合物、およびこの組成物、およびこの使用
|
|
GB2453819A
(en)
|
2006-01-09 |
2009-04-22 |
Btg Int Ltd |
Modulators of hypoxia inducible factor-1 and related uses
|
|
WO2007082899A1
(en)
|
2006-01-17 |
2007-07-26 |
Vib Vzw |
Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
|
|
US20070208053A1
(en)
|
2006-01-19 |
2007-09-06 |
Arnold Lee D |
Fused heterobicyclic kinase inhibitors
|
|
JP4801451B2
(ja)
|
2006-01-19 |
2011-10-26 |
株式会社日立ハイテクノロジーズ |
走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法
|
|
ITMI20060179A1
(it)
|
2006-02-02 |
2007-08-03 |
Abiogen Pharma Spa |
Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse
|
|
WO2007101204A1
(en)
|
2006-02-27 |
2007-09-07 |
Alcon Research, Ltd. |
Method of treating glaucoma
|
|
AR059733A1
(es)
|
2006-03-07 |
2008-04-23 |
Smithkline Beecham Corp |
Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
|
|
US7588924B2
(en)
|
2006-03-07 |
2009-09-15 |
Procter & Gamble Company |
Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
|
|
ES2288117B1
(es)
|
2006-05-08 |
2008-12-01 |
Combino Pharm, S.L. |
Composicion farmaceutica solida de gabapentina.
|
|
WO2007136990A2
(en)
|
2006-05-16 |
2007-11-29 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
|
JO2934B1
(en)
|
2006-06-23 |
2015-09-15 |
سميث كلاين بيتشام كوربوريشن |
Prolyl hydroxylase inhibitors
|
|
BRPI0713350B1
(pt)
|
2006-06-26 |
2022-04-12 |
Akebia Therapeutics Inc |
Composto, e, composição
|
|
CL2008000065A1
(es)
|
2007-01-12 |
2008-09-22 |
Smithkline Beecham Corp |
Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia.
|
|
TW200845991A
(en)
|
2007-01-12 |
2008-12-01 |
Smithkline Beecham Corp |
N-substituted glycine derivatives: hydroxylase inhibitors
|
|
JP2008201711A
(ja)
*
|
2007-02-20 |
2008-09-04 |
Ss Pharmaceut Co Ltd |
システイン臭が低減された固形製剤
|
|
EP2155680B1
(en)
|
2007-04-18 |
2013-12-04 |
Amgen, Inc |
Indanone derivatives that inhibit prolyl hydroxylase
|
|
CA2683758A1
(en)
|
2007-04-18 |
2008-10-30 |
Merck & Co., Inc. |
Novel 1,8-naphthyridine compounds
|
|
ES2389063T3
(es)
|
2007-05-04 |
2012-10-22 |
Amgen, Inc |
Derivados de tienopiridina y tiazolopiridina que inhiben la actividad prolil hidroxilasa
|
|
EP2160187B1
(en)
|
2007-05-16 |
2013-05-22 |
Merck Sharp & Dohme Corp. |
Spiroindalones
|
|
CA2687306A1
(en)
|
2007-05-18 |
2008-11-27 |
Bayer Schering Pharma Aktiengesellschaft |
Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
|
|
EP2186528B1
(en)
|
2007-08-06 |
2014-03-19 |
Senju Pharmaceutical Co., Ltd. |
Pharmaceutical containing hif-1 alpha and hif-2 alpha expression inhibitor
|
|
TW200908984A
(en)
|
2007-08-07 |
2009-03-01 |
Piramal Life Sciences Ltd |
Pyridyl derivatives, their preparation and use
|
|
CA2696725A1
(en)
|
2007-08-10 |
2009-03-26 |
Crystalgenomics, Inc. |
Pyridine derivatives and methods of use thereof
|
|
WO2009035534A2
(en)
|
2007-09-07 |
2009-03-19 |
The Cleveland Clinic Foundation |
Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
|
|
WO2009039321A1
(en)
|
2007-09-19 |
2009-03-26 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
|
WO2009039323A1
(en)
|
2007-09-19 |
2009-03-26 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
|
WO2009043093A1
(en)
|
2007-10-04 |
2009-04-09 |
Newsouth Innovations Pty Limited |
Hif inhibition
|
|
WO2009049112A1
(en)
|
2007-10-10 |
2009-04-16 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
|
WO2009067790A1
(en)
|
2007-11-26 |
2009-06-04 |
Uti Limited Partnership |
STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION
|
|
US20100305133A1
(en)
|
2007-11-30 |
2010-12-02 |
Smithkline Beecham Corporation |
Prolyl Hydroxylase Inhibitors
|
|
WO2009070644A1
(en)
|
2007-11-30 |
2009-06-04 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
|
US8269008B2
(en)
|
2007-12-03 |
2012-09-18 |
Fibrogen, Inc. |
Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
|
|
WO2009086044A1
(en)
|
2007-12-19 |
2009-07-09 |
Smith Kline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
|
WO2009086592A1
(en)
|
2008-01-04 |
2009-07-16 |
Garvan Institute Of Medical Research |
Method of increasing metabolism
|
|
EP2252619B1
(en)
|
2008-01-11 |
2013-10-09 |
Fibrogen, Inc. |
Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
|
|
PT2268618E
(pt)
|
2008-03-03 |
2015-10-12 |
Novartis Ag |
Compostos e composições moduladores da actividade tlr
|
|
PE20110409A1
(es)
|
2008-07-23 |
2011-06-22 |
Hoffmann La Roche |
Compuestos heterociclicos antiviricos
|
|
JP2012502900A
(ja)
|
2008-09-15 |
2012-02-02 |
カシナ ライラ イノバ ファーマシューティカルズ プライベート リミテッド |
抗癌剤並びにそれに関する転移性悪性黒色腫及び他の癌についての使用
|
|
WO2010056767A1
(en)
|
2008-11-14 |
2010-05-20 |
Fibrogen, Inc. |
Thiochromene derivatives as hip hydroxylase inhibitors
|
|
SI2415771T1
(sl)
|
2009-03-31 |
2013-12-31 |
Kissei Pharmaceutical Co., Ltd. |
Derivat indolizina in njegova uporaba v medicinske namene
|
|
EP3698794A1
(en)
|
2009-11-06 |
2020-08-26 |
Aerpio Therapeutics, Inc. |
Compositions and methods for treating colitis
|
|
AR079343A1
(es)
|
2009-12-21 |
2012-01-18 |
Lilly Co Eli |
Compuesto de acido 2-amino-4-(4h-1,2,4-triazol-3-ilsulfanil)biciclo[3.1.0]hexano-2,6-dicarboxilico, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar un trastorno psiquiatrico
|
|
WO2012097331A1
(en)
|
2011-01-13 |
2012-07-19 |
Fibrogen, Inc. |
Methods for increasing reticulocyte hemoglobin content
|
|
NO2686520T3
(https=)
|
2011-06-06 |
2018-03-17 |
|
|
|
EP2717870B1
(en)
|
2011-06-06 |
2017-09-27 |
Akebia Therapeutics Inc. |
Composition for stabilizing hypoxia inducible factor-2 alpha useful for treating cancer
|
|
US20130022974A1
(en)
|
2011-06-17 |
2013-01-24 |
The Regents Of The University Of Michigan |
Dna methylation profiles in cancer
|
|
US9206134B2
(en)
|
2011-07-22 |
2015-12-08 |
Beijing Betta Pharmaceuticals Co. Ltd. |
Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
|
|
US20140309256A1
(en)
|
2011-11-09 |
2014-10-16 |
Fibrogen, Inc. |
Therapeutic Method
|
|
AU2013347264B2
(en)
|
2012-11-19 |
2016-10-27 |
Afyx Therapeutics A/S |
Dispersible tablet
|
|
EP2983674A4
(en)
*
|
2013-04-08 |
2017-05-10 |
Dennis M. Brown |
Therapeutic benefit of suboptimally administered chemical compounds
|
|
KR20210104173A
(ko)
*
|
2013-06-06 |
2021-08-24 |
피브로겐, 인크. |
Hif 하이드록실라제 억제자의 약학적 제형
|
|
SG10201910773VA
(en)
|
2013-06-13 |
2020-01-30 |
Akebia Therapeutics Inc |
Compositions and methods for treating anemia
|
|
RU2016109125A
(ru)
|
2013-08-16 |
2017-09-22 |
Огайо Стейт Инновейшн Фаундейшн |
Композиции и способы модуляции метилирования днк
|
|
AR099354A1
(es)
|
2013-11-15 |
2016-07-20 |
Akebia Therapeutics Inc |
Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos
|
|
WO2015112831A1
(en)
|
2014-01-23 |
2015-07-30 |
Akebia Therapeutics, Inc. |
Compositions and methods for treating ocular diseases
|
|
US10617716B2
(en)
|
2014-12-16 |
2020-04-14 |
Urgo Us, Inc. |
Hypochlorous acid formulations and methods for treating skin conditions
|
|
AU2016209126A1
(en)
|
2015-01-23 |
2017-08-10 |
Akebia Therapeutics, Inc. |
Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
|
|
US20180065933A1
(en)
|
2015-03-20 |
2018-03-08 |
Akebia Therapeutics, Inc. |
Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
|
|
US11324734B2
(en)
*
|
2015-04-01 |
2022-05-10 |
Akebia Therapeutics, Inc. |
Compositions and methods for treating anemia
|